Company Overview
BriaCell Therapeutics Corp. operates as a pre-clinical stage immuno-oncology entity dedicated to developing targeted immunotherapies designed to transform cancer care, with its primary focus currently on end-stage breast cancer. The company functions within the Healthcare sector and the Biotechnology industry, positions that define its approach to high-risk, high-reward research and development rather than established commercial product lines. Its current market capitalization stands at $27.19M, while annual revenue and employee count are not disclosed in the available financial data, indicating a very early-stage enterprise. The combination of a sub-$30M market cap and the absence of reported revenue figures suggests the company remains in a capital-intensive development phase where valuation is driven entirely by pipeline potential rather than current earnings or sales volume.
Financial Health
The company reports revenue of N/A for the trailing twelve months, a net income of $-29,637,656, and an EBITDA of $-30,630,110, reflecting significant operational losses typical of pre-clinical biotechnology firms. The substantial gap between the zero revenue and the negative net income reveals a cost structure dominated by research expenses, clinical trial costs, and general administrative overheads rather than cost of goods sold. Free cash flow stands at $-20,493,214, indicating that the company is consuming cash to fuel its development programs and lacks the current financial flexibility to fund operations without external capital raises or strategic partnerships. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet generated positive gross profit or operating income from its commercial or clinical activities. The company holds $29.90M in cash, while debt is listed as N/A, suggesting a conservative balance sheet that relies on liquid assets to offset ongoing burn rates. The current ratio is reported at 10.10, a figure that indicates exceptionally strong short-term liquidity relative to current liabilities, providing a substantial buffer against immediate financial obligations. Return on Equity is -179.2% and Return on Assets is -89.4%, metrics that reveal the company is currently destroying value per unit of capital employed due to its heavy investment in R&D and the lack of revenue generation.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the lack of earnings, while the forward P/E is listed as -9.62, implying that the market prices the stock based on future expectations of profitability that have not yet materialized. The price-to-book ratio is 0.88, suggesting that the market values the company's equity at a discount to its book value, which is common for speculative biotechnology firms with intangible asset-heavy balance sheets. The price-to-sales ratio is N/A and the EV/EBITDA is 0.11, alternative valuation metrics that suggest the company is valued primarily on its asset base and potential rather than current sales performance or earnings multiples. The 52-week high is $98.20 and the 52-week low is $3.60, meaning the current market price sits significantly below the recent peak, reflecting high volatility and the typical wide trading ranges associated with small-cap biotech stocks. The beta is 1.80, a figure that indicates the stock's price volatility is more than double that of the broader market, exposing holders to heightened risk during periods of market turbulence.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings expansion versus revenue expansion in the traditional sense. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the company reinvests all available capital and future earnings into its research and development pipeline rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of current income generation and reported growth rates, relying instead on the successful advancement of its lead candidate, Bria-IMT, through Phase 3 clinical trials to eventually achieve commercial viability. This profile necessitates continuous capital infusion to sustain operations until the company transitions from a cash-burning pre-clinical stage to a revenue-producing commercial entity.